ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • IgG4 Related Disease and fibrosis
  • IgG4 Related Disease and flow cytometry
  • IgG4 Related Disease and laboratory tests
  • IgG4 Related Disease and malignancy
  • IgG4 Related Disease and morbidity and mortality
  • IgG4 Related Disease and outcomes
  • IgG4 Related Disease and phenotypes
  • IgG4 Related Disease and Plasmablasts
  • IgG4 Related Disease and Pulmonary Involvement
  • IgG4 Related Disease and Retroperitoneal Fibrosing
  • IgG4 Related Disease and rituximab
  • IgG4 Related Disease and salivary gland
  • IgG4 Related Disease and severity
  • IgG4 Related Disease and tobacco use
  • IgG4 Related Disease and treatment
  • IgG4 Related Disease and ultrasonography
  • IgG4 Related Disease and vasculitis
  • IGRA
  • Iguratimod
  • IL and INF
  • IL-1
  • IL-1 and anakinra
  • IL-1 and IL-6
  • IL-1 and interferons
  • IL-1 and major histocompatibility complex (MHC)
  • IL-1 and nod-like receptor (NLR)
  • IL-1 and osteoarthritis
  • IL-1 and polymorphism
  • IL-1 and stress
  • IL-1 and T-Regulatory Cells
  • IL-1/IL-18
  • IL-1/IL-18 and inflammasome activation
  • IL-1/IL-18 and salivary gland
  • IL-1/IL-18 and Still's disease
  • IL-13Ra1
  • IL-17
  • IL-17 and psoriasis
  • IL-17 and TNFi
  • IL-17A
  • IL-17A and psoriasis
  • IL-1ß blockade
  • IL-2
  • IL-23
  • IL-23 and autoantibodies
  • IL-23 and IL-1
  • IL-23 and Janus kinase (JAK)
  • IL-23 and psoriatic arthritis
  • IL-23 and Sjogren's syndrome
  • IL-23 and spondylarthritis
  • IL-23 and spondylarthropathy
  • IL-23 and toll-like receptors
  • IL-23 minicircle and neutrophils
  • IL-6
  • IL-6 and atherosclerosis
  • IL-6 and Biologics
  • IL-6 and Chromatin looping
  • IL-6 and cytokines
  • IL-6 and IL-6R signaling
  • IL-6 and lupus nephritis
  • IL-6 and osteoarthritis
  • IL-6 and rheumatoid arthritis
  • IL-6 and rheumatoid arthritis (RA)
  • IL-6 and systemic sclerosis
  • IL-6 and Takayasu.s arteritis
  • IL-6 receptor inhibitor
  • IL-6R signaling
  • IL-6R signaling and ETS2
  • IL-6R signaling and Rheumatoid arthritis
  • IL-6R signaling and T cells
  • il-8 and MRP8
  • IL6
  • IL6 and MMP9
  • Il6 inhibitor
  • il7 and lymphocytes
  • ILAR
  • ILD
  • illness and doctor-patient relationship
  • Illness Perception
  • Illness perceptions
  • iloprost treatment
  • Image Analysis
  • Imaging
  • Imaging and cardiovascular disease
  • Imaging and diagnostic imaging
  • Imaging and Disease Activity
  • Imaging and giant cell arteritis
  • Imaging and gout
  • Imaging and joint damage
  • Imaging and large vessel vasculitis
  • Imaging and Lupus
  • Imaging and platelets
  • Imaging and psoriasis
  • Imaging and radiology
  • Imaging and reversible cerebrovascular vasoconstriction
  • Imaging and rheumatoid arthritis (RA)
  • Imaging and spondylarthritis
  • Imaging and systemic sclerosis
  • Imaging and takayasu arteritis
  • Imaging and ultrasound
  • imaging techniques
  • imaging techniques and bone density
  • imaging techniques and immune activation
  • imaging techniques and inflammation
  • imaging techniques and inflammatory arthritis
  • imaging techniques and juvenile idiopathic arthritis (JIA)
  • imaging techniques and lupus nephritis
  • imaging techniques and monocytes
  • imaging techniques and neutrophils
  • imaging techniques and osteoarthritis
  • imaging techniques and pain
  • imaging techniques and radiography
  • imaging techniques and rheumatoid arthritis (RA)
  • Imaging techniques and spondylarthritis
  • imaging techniques and spondylarthropathy
  • imaging techniques and systemic lupus erythematosus (SLE)
  • Imaging techniques and systemic sclerosis
  • imaging techniques and tocilizumab
  • imaging techniques and treatment options
  • imaging techniques and ultrasonography
  • imaging techniques and uric acid
  • imaging techniques and vasculitis
  • Imatinib
  • imatinib and systemic sclerosis
  • immate immune system
  • Immune
  • immune activation
  • immune activation and B cells
  • immune activation and inflammatory arthritis
  • immune activation and mouse model
  • immune activation and rheumatoid arthritis (RA)
  • immune activation and T-cell
  • Immune checkpoint inhibitor
  • Immune checkpoint inhibitors
  • immune checkpoint molecules and rheumatoide arthritis
  • immune deficiency
  • immune deficiency and infection
  • immune deficiency and macrophage activation syndrome
  • Immune Dysregulation
  • Immune Dysregulation and ankylosing spondylitis (AS)
  • Immune Dysregulation and auto-immunity
  • Immune Dysregulation and giant cell arteritis
  • Immune Dysregulation and Synovial Immune Biology
  • IMMUNE MEDIATED INFLAMMATORY DISEASES
  • immune reconstitution
  • Immune regulation
  • Immune regulation and Gene Expression
  • Immune regulation and T cells
  • immune response
  • immune response and inflammation
  • Immune response and inflammatory myositis
  • immune response and infliximab
  • immune response and neutrophils
  • immune response and proteomics
  • immune response and rheumatoid arthritis (RA)
  • immune response and spondylarthritis
  • immune response and systemic lupus erythematosus (SLE)
  • immune response and systemic sclerosis
  • immune response and tolerance
  • immune response and vaccines
  • immune response and vasculitis
  • immune system development and newborn
  • immune tolerance
  • immune tolerance and autologous transplantation
  • immune tolerance and collagen
  • immune tolerance and lupus dermatitis
  • immune tolerance and plasma cells
  • immune tolerance and rheumatoid arthritis
  • immune tolerance and systemic lupus erythematosus (SLE)
  • immune tolerance and uric acid
  • Immune-Checkpoint Inhibitor Inflammatory Arthritis
  • immune-mediated adverse events
  • immune-mediated inflammatory disease
  • Immune-mediated Necrotizing Myopathy
  • immune-related adverse event
  • immune-related adverse events
  • immunity
  • immunity and rheumatoid arthritis (RA)
  • Immunodeficiency
  • immunodeficiency and infection
  • Immunofluorescence
  • Immunogenetics
  • Immunogenetics and Gene Expression
  • Immunogenetics and genetics
  • Immunogenetics and rheumatoid arthritis
  • Immunogenetics and treatment
  • Immunogenicity
  • Immunoglobulin (IG)
  • immunoglobulin (IG) and citrullination
  • immunoglobulin (IG) and immune activation
  • immunoglobulin (IG) and infection
  • immunoglobulin (IG) and inflammation
  • immunoglobulin (IG) and interleukins (IL)
  • immunoglobulin (IG) and interstitial lung disease
  • Immunoglobulin (IG) and laboratory tests
  • immunoglobulin (IG) and microparticles
  • Immunoglobulin (IG) and myopathy
  • immunoglobulin (IG) and osteoclastogenesis
  • Immunoglobulin (IG) and positron emission tomography (PET)
  • immunoglobulin (IG) and proteomics
  • immunoglobulin (IG) and rheumatoid arthritis (RA)
  • First |
  • « Previous Page
  • 24
  • 25
  • 26
  • 27
  • 28
  • [29]
  • 30
  • 31
  • 32
  • 33
  • 34
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology